uracil has been researched along with Heart Failure in 29 studies
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder
Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In patients with type 2 diabetes and recent acute coronary syndromes, alogliptin did not increase the risk of heart failure outcomes." | 9.20 | Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. ( Bakris, GL; Cannon, CP; Cushman, WC; Fleck, PR; Kupfer, S; Lam, H; Mehta, CR; Menon, V; Perez, AT; White, WB; Wilson, C; Zannad, F, 2015) |
| "In patients with type 2 diabetes and recent acute coronary syndromes, alogliptin did not increase the risk of heart failure outcomes." | 5.20 | Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. ( Bakris, GL; Cannon, CP; Cushman, WC; Fleck, PR; Kupfer, S; Lam, H; Mehta, CR; Menon, V; Perez, AT; White, WB; Wilson, C; Zannad, F, 2015) |
| "There are data from studies using sitagliptin, saxagliptin, and alogliptin showing that these agents may increase the risk of hospitalization for heart failure." | 4.90 | Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure? ( Clifton, P, 2014) |
| " In the cardiovascular subset, there was an SDR for heart failure with linagliptin (EB05 = 2782." | 3.88 | Cardiovascular safety signals with dipeptidyl peptidase-4 inhibitors: A disproportionality analysis among high-risk patients. ( Alexander, GC; Baksh, SN; McAdams-DeMarco, M; Segal, JB, 2018) |
| "We investigated the effects of a DPP-4 inhibitor, alogliptin, on atrial fibrillation (AF) in a rabbit model of heart failure caused by ventricular tachypacing (VTP)." | 3.81 | Alogliptin, a dipeptidyl peptidase-4 inhibitor, regulates the atrial arrhythmogenic substrate in rabbits. ( Hirai, M; Inden, Y; Murohara, T; Shimano, M; Takefuji, M; Tsuji, Y; Yamamoto, T; Yanagisawa, S; Yoshida, N, 2015) |
| "Early after an ACS, patients with type 2 diabetes mellitus experience a significant burden of HF events and recurrent ACS." | 2.87 | Early and Chronic Dipeptidyl-Peptidase-IV Inhibition and Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After an Acute Coronary Syndrome: A Landmark Analysis of the EXAMINE Trial. ( Bakris, GL; Cannon, CP; Cushman, WC; Liu, Y; Sharma, A; White, WB; Zannad, F, 2018) |
| "Conclusions In patients with type 2 diabetes mellitus and recent acute coronary syndrome, average BP s <130/80 mm Hg were associated with worsened cardiovascular outcomes." | 2.87 | Average Clinician-Measured Blood Pressures and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Ischemic Heart Disease in the EXAMINE Trial. ( Bakris, GL; Bergenstal, R; Cannon, CP; Cushman, WC; Heller, SR; Jalil, F; Liu, Y; Mehta, C; White, WB; Zannad, F, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (17.24) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (6.90) | 29.6817 |
| 2010's | 18 (62.07) | 24.3611 |
| 2020's | 4 (13.79) | 2.80 |
| Authors | Studies |
|---|---|
| Sharma, A | 2 |
| Vaduganathan, M | 1 |
| Ferreira, JP | 1 |
| Liu, Y | 4 |
| Bakris, GL | 5 |
| Cannon, CP | 5 |
| White, WB | 7 |
| Zannad, F | 6 |
| Nabavizadeh, P | 1 |
| Steen, DL | 1 |
| Shen, S | 1 |
| Sewanan, LR | 1 |
| Campbell, SG | 1 |
| Chen, YJ | 1 |
| Chien, CS | 1 |
| Chiang, CE | 1 |
| Chen, CH | 1 |
| Cheng, HM | 1 |
| Kaneko, M | 1 |
| Narukawa, M | 1 |
| Hwang, YC | 1 |
| Morrow, DA | 1 |
| Bergenstal, R | 2 |
| Heller, S | 1 |
| Mehta, C | 2 |
| Cushman, W | 1 |
| Baksh, SN | 1 |
| McAdams-DeMarco, M | 1 |
| Segal, JB | 1 |
| Alexander, GC | 1 |
| Cushman, WC | 3 |
| Sano, M | 1 |
| Jalil, F | 1 |
| Heller, SR | 1 |
| Clifton, P | 1 |
| Yamamoto, T | 1 |
| Shimano, M | 1 |
| Inden, Y | 1 |
| Takefuji, M | 1 |
| Yanagisawa, S | 1 |
| Yoshida, N | 1 |
| Tsuji, Y | 1 |
| Hirai, M | 1 |
| Murohara, T | 2 |
| Menon, V | 1 |
| Perez, AT | 1 |
| Fleck, PR | 1 |
| Mehta, CR | 1 |
| Kupfer, S | 2 |
| Wilson, C | 1 |
| Lam, H | 1 |
| Riche, DM | 1 |
| Davis, C | 1 |
| Derosa, G | 1 |
| Maffioli, P | 1 |
| Hülsmann, M | 1 |
| Pacher, R | 1 |
| Neuhold, S | 1 |
| Špinar, J | 1 |
| Špinarová, L | 1 |
| Vítovec, J | 1 |
| Aoyama, M | 1 |
| Kawase, H | 1 |
| Bando, YK | 1 |
| Monji, A | 1 |
| Baker, WL | 1 |
| Jermendy, G | 1 |
| Schernthaner, G | 1 |
| Cahn, A | 1 |
| Raz, I | 1 |
| HELLMAN, E | 1 |
| ALTCHEK, R | 1 |
| ENSELBERG, CD | 1 |
| GILBERT, RP | 1 |
| FLACK, HA | 1 |
| Yajima, T | 1 |
| Furukawa, Y | 1 |
| Ishii, Y | 1 |
| Hattori, Y | 1 |
| Matsumoto, N | 1 |
| Yamamoto, M | 1 |
| Yamaoka, Y | 1 |
| Fujihara, M | 1 |
| Fujita, M | 1 |
| Kuniki, H | 1 |
| Branca, MA | 1 |
| Meerson, FZ | 1 |
| Buckley, NM | 1 |
| Kapel'ko, VI | 1 |
| Shenderov, SM | 1 |
| Klykov, NV | 1 |
| Sánchez, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment With Alogliptin in Addition to Standard of Care in Subjects With Type 2 Diabetes and Acute Coronary Syndrome[NCT00968708] | Phase 3 | 5,380 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Primary Major Adverse Cardiac Events were defined as a composite of cardiovascular death, nonfatal myocardial infarction and nonfatal stroke; these events were adjudicated by an independent cardiovascular endpoints committee. (NCT00968708)
Timeframe: From randomization until the adjudication cut-off date of May 31 2013 (maximum time on study was 41 months).
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 11.8 |
| Alogliptin | 11.3 |
Secondary MACE composite consisted of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or urgent revascularization due to unstable angina; these events were adjudicated by an independent cardiovascular endpoint committee. (NCT00968708)
Timeframe: From randomization until the adjudication cut-of date of May 31 2013 (maximum time on study was 41 months).
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 13.4 |
| Alogliptin | 12.7 |
7 reviews available for uracil and Heart Failure
| Article | Year |
|---|---|
From Genetic Mutations to Molecular Basis of Heart Failure Treatment: An Overview of the Mechanism and Implication of the Novel Modulators for Cardiac Myosin.
Topics: Benzylamines; Cardiac Myosins; Heart Failure; Humans; Molecular Targeted Therapy; Myocytes, Cardiac; | 2021 |
Mechanism by which dipeptidyl peptidase-4 inhibitors increase the risk of heart failure and possible differences in heart failure risk.
Topics: Adult; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Femal | 2019 |
Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure?
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Heart Failure | 2014 |
[The TECOS, EXAMINE and SAVOR studies--how do they differ and what are their outcomes?].
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors | 2015 |
Cardiovascular Effects of Incretin-Based Therapies.
Topics: Adamantane; Cardiovascular Diseases; Cardiovascular System; Clinical Trials as Topic; Diabetes Melli | 2016 |
[Cardiovascular safety of incretin-based antidiabetic treatment - results of completed clinical trials].
Topics: Adamantane; Cardiovascular System; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV In | 2016 |
[Depletion therapy of chronic congestive heart failure].
Topics: Bloodletting; Carbonic Anhydrase Inhibitors; Chlorides; Diet, Sodium-Restricted; Digitalis Glycoside | 1968 |
5 trials available for uracil and Heart Failure
17 other studies available for uracil and Heart Failure
| Article | Year |
|---|---|
Highlights from the European society of cardiology congress 2020.
Topics: Atrial Fibrillation; Benzhydryl Compounds; Benzylamines; Cardiomyopathy, Hypertrophic; Cardiovascula | 2021 |
Evidence for synergy between sarcomeres and fibroblasts in an in vitro model of myocardial reverse remodeling.
Topics: Actomyosin; Animals; Animals, Newborn; Benzamides; Benzylamines; Cardiac Myosins; Cell Line; Dioxole | 2021 |
Assessment of the Risk of Hospitalization for Heart Failure With Dipeptidyl Peptidase-4 Inhibitors, Saxagliptin, Alogliptin, and Sitagliptin in Patients With Type 2 Diabetes, Using an Alternative Measure to the Hazard Ratio.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Heart Failure | 2017 |
Cardiovascular safety signals with dipeptidyl peptidase-4 inhibitors: A disproportionality analysis among high-risk patients.
Topics: Adamantane; Administration, Oral; Adverse Drug Reaction Reporting Systems; Aged; Bayes Theorem; Data | 2018 |
Alogliptin, a dipeptidyl peptidase-4 inhibitor, regulates the atrial arrhythmogenic substrate in rabbits.
Topics: Animals; Atrial Fibrillation; Blotting, Western; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; E | 2015 |
EXAMINE: targeting risk and treatment in diabetes.
Topics: Acute Coronary Syndrome; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Female; Heart Failure | 2015 |
EXAMINE: targeting risk and treatment in diabetes.
Topics: Acute Coronary Syndrome; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Female; Heart Failure | 2015 |
EXAMINE: targeting risk and treatment in diabetes.
Topics: Acute Coronary Syndrome; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Female; Heart Failure | 2015 |
EXAMINE: targeting risk and treatment in diabetes - Authors' reply.
Topics: Acute Coronary Syndrome; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Female; Heart Failure | 2015 |
Dipeptidyl Peptidase 4 Inhibition Alleviates Shortage of Circulating Glucagon-Like Peptide-1 in Heart Failure and Mitigates Myocardial Remodeling and Apoptosis via the Exchange Protein Directly Activated by Cyclic AMP 1/Ras-Related Protein 1 Axis.
Topics: Animals; Apoptosis; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Dipeptidyl Peptidase 4; Dipept | 2016 |
Is the Use of DPP-4 Inhibitors Associated With an Increased Risk for Heart Failure? Lessons From EXAMINE, SAVOR-TIMI 53, and TECOS.
Topics: Adamantane; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV | 2016 |
Therapeutic and toxic effects of a new oral diuretic (1-propyl-3-ethyl-6-aminouracil).
Topics: Diuretics; Heart Failure; Humans; Uracil; Wounds and Injuries | 1952 |
A therapeutic evaluation of four aminouracil compounds.
Topics: Diuretics; Heart Failure; Uracil | 1953 |
[Two cases of advanced pancreatic cancer responding to gemcitabine with long survival of 2 years].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cholestasis; Deoxycytidine; Drug Ad | 2004 |
BiDil raises questions about race as a marker.
Topics: Biomarkers; Black People; Clinical Trials as Topic; Dihydropyrimidine Dehydrogenase Deficiency; Dihy | 2005 |
[Effect of nucleosides on the contractile function of the myocardium in the emergency stage of compensatory function of the heart].
Topics: Animals; Aortic Diseases; Heart Failure; Heart Ventricles; Hypoxanthines; Male; Nucleosides; Rabbits | 1966 |
[Use of pentoxyl in the treatment of chronic cardiac insufficiency].
Topics: Adult; Aged; Chronic Disease; Drug Synergism; Female; Heart Failure; Humans; Male; Middle Aged; Rheu | 1975 |